SYD 1875
Alternative Names: Anti-5T4 antibody drug conjugate - Byondis; SYD-1875Latest Information Update: 28 Mar 2023
At a glance
- Originator Synthon
- Developer Byondis
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Alkylating agents; DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV, Infusion)
- 26 Jan 2023 Byondis completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Belgium (IV) (NCT04202705)